Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Capital Raise

Aclaris Therapeutics Shares Surge 15% in 11 Days Since $50 Million Underwritten Offering

Aclaris Therapeutics Raises $50 Million in Underwritten Stock and Warrant Offering

+15.04% in 11 days $3.79 when we broke this story → $4.36 at 12:26 PM ET, 11 Nov 2026

Aclaris Therapeutics has entered into an underwriting agreement to raise $50.0 million through the sale of common stock and pre-funded warrants. The offering is designed to provide the biotechnology firm with approximately $46.7 million in net proceeds to support its clinical development programs.

Doctor, medical, medicine, health. Stock photo illustrating Aclaris Therapeutics' capital raise story.
Aclaris Therapeutics, Inc. · Healthcare · Photo: DarkoStojanovic / Pixabay
Key numbers
Deal value$50M
Share of market cap9.0%

Key highlights

  • Offering includes 7,785,714 shares of common stock and pre-funded warrants for 6,500,000 shares
  • Common stock priced at $3.50 per share with warrants priced at $3.49999
  • Estimated net proceeds of $46.7 million after underwriting discounts and expenses
  • Closing of the capital raise is scheduled for October 28, 2026
  • Leerink Partners, Piper Sandler, and Cantor Fitzgerald serving as joint representatives

What Is the Capital Raise?

Aclaris Therapeutics entered into an underwriting agreement on October 27, 2026, to issue 7,785,714 shares of common stock alongside pre-funded warrants for another 6,500,000 shares. Priced at $3.50 per share, the transaction is led by Leerink Partners, Piper Sandler, and Cantor Fitzgerald. The pre-funded warrants carry a nominal exercise price of $0.00001 and have no expiration date, essentially functioning as equity-equivalent instruments. Gross proceeds are estimated at $50.0 million, resulting in approximately $46.7 million in net capital after underwriting discounts and offering expenses. The transaction is slated to close on October 28, 2026, subject to customary conditions.

Aclaris Therapeutics, Inc. share price · last month
Line chart of Aclaris Therapeutics, Inc.'s share price over the last month, from $3.48 on 19 Oct → $3.60 on 16 Nov; our story on 27 Oct at $3.79.

Down 4.9% since our story on 27 Oct: $3.79 when we broke it → $3.60 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$3.48
20 Oct$3.77
21 Oct$3.81
22 Oct$3.83
23 Oct$3.75
26 Oct$3.79
27 Oct$3.79
28 Oct$3.96
29 Oct$3.99
30 Oct$3.97
2 Nov$3.80
3 Nov$3.74
4 Nov$3.68
5 Nov$3.61
6 Nov$3.90
9 Nov$4.24
10 Nov$4.15
11 Nov$4.34
12 Nov$4.00
13 Nov$3.92
16 Nov$3.60

Use of Proceeds

  • Funding general corporate purposes and working capital requirements
  • Advancing the clinical development of the company's biopharmaceutical pipeline
  • Supporting the planned Phase 2b clinical trial for ATI-052 in eosinophilic esophagitis
  • Strengthening the balance sheet to meet projected operational expenses through 2028

Strategic Rationale

The timing of this $50 million raise follows Aclaris's recent clinical roadmap disclosures, specifically the planned initiation of Phase 2b trials for ATI-052 in early 2027. This infusion complements previous at-the-market equity programs and private placements conducted throughout 2024 and 2025, indicating a strategy of continuous capital layering to fund research. By utilizing an underwritten offering instead of relying solely on existing at-the-market facilities, the company secures a guaranteed block of capital in a single window. This immediate liquidity is intended to support upcoming clinical milestones while maintaining a cash runway that management previously projected would last through the end of 2028.

Business Overview

Aclaris Therapeutics is a clinical-stage biopharmaceutical firm based in Wayne, Pennsylvania, focused on developing novel drug candidates for immuno-inflammatory diseases. The company’s research and development efforts target specific kinase pathways to address unmet medical needs in dermatology and immunology. Operating without significant product revenue, Aclaris relies on capital markets and strategic partnerships to fund its investigative pipeline. Its current portfolio includes multiple candidates undergoing clinical evaluation, with value creation driven by trial results and regulatory progress. The company’s structure is typical for the biotechnology sector, where high research costs precede the potential commercialization of therapeutic assets.

Earlier announcements by Aclaris Therapeutics, Inc.
DateAnnouncementAmount
06 Aug 2026At-the-market equity offering programSource: stocktitan.net$150.0 Million
11 Mar 2026At-the-market sale of common stockSource: investor.aclaristx.com$20.0 Million
09 Mar 2026At-the-market sale of common stockSource: cbonds.com$39.8 Million
27 Feb 2025At-the-market equity offering programSource: SEC filing$100.0 Million
18 Nov 2024Private placement of common stockSource: globenewswire.com$80.0 Million
Aclaris Therapeutics, Inc. · financial snapshot
Share price$3.79
Market cap$558M
Revenue (annual)$8M
1-month price change-26.41%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Aclaris Therapeutics, Inc. announcing an underwritten stock offering.

Read the filing ↗
All Aclaris Therapeutics, Inc. filings and newsView all →

Track Aclaris Therapeutics, Inc. live

Get the next Aclaris Therapeutics, Inc. SEC filing seconds after it lands.

More from Aclaris Therapeutics, Inc.

All →

More in Capital Raise

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.